NCT06656221
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 1 with changes below, 1 re-verified with no change.
- Study First Submitted
Endpoints
Primary
Complete Response (CR) Rate
Timeframe: Up to 2 years
Secondary (6)
Objective Response Rate (ORR)
Duration of Response (DoR)
Duration of Complete Response (DoCR)
Progression-Free Survival (PFS)
Overall Survival (OS)
Show 1 moreShow less
Incidence and severity of adverse events
Arms and interventions
Glofitamab-Orelabrutinib-BortezomibExperimental
Participants will receive 2000 mg of obinutuzumab on Days 1-2 of Cycle 1, 2.5 mg of glofitamab on Day 8 of Cycle 1, 10 mg of glofitamab on Day 15 of Cycle 1, followed by 30 mg of glofitamab on Day 1 of Cycles 2-12. Participants will receive 1.6 mg/m² of bortezomib on Days 1, 8, and 15 of Cycles 1-12. Participants will receive 150 mg/day of orelabrutinib on Days 1-21of Cycles 1-12. The duration of one cycle is 21 days.
Drugs: Obinutuzumab, Glofitamab, Bortezomib, Orelabrutinib